A Multicentre, Randomized, Double-blinded, Placebo-controlled Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTT11 in Healthy Participants and Participants with Moderate-to-severe Thyroid Eye Disease
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs SCTT 11 (Primary)
- Indications Graves ophthalmopathy
- Focus Adverse reactions
- Sponsors Sinocelltech
- 16 Jan 2025 New trial record